Abstract
Neuronal activity triggers multiple signal transduction pathways and potently regulates gene expression in the brain. In the central nervous system, in addition to the synaptic input, neurons are subject to neuromodulatory influences that can activate the same signaling elements. However, the principles that govern the interaction of neuromodulators and neuronal activity in the regulation of gene expression are unclear. Here, we examine how serotonergic neuromodulation interacts with neuronal activity in the regulation of gene expression in hippocampal neurons. We show that cAMP-response element binding protein (CREB) phosphorylation and gene expression were stimulated by serotonin (5-HT) in the absence of neuronal activity. In contrast, in the presence of neuronal activity, 5-HT inhibited gene expression down to the baseline, although neuronal activity alone was sufficient to maximally activate gene expression. The ability of 5-HT to stimulate CREB phosphorylation in the absence of neuronal activity or inhibit CREB phosphorylation during activity was due to a tight balance between protein kinases and phosphatases that could be physiologically tilted by different serotonergic receptors or exogenously influenced by phosphatase and kinase inhibitors. Taken together, these results suggest a reciprocal inhibitory interaction between neuronal activity and 5-HT in the regulation of cAMP response element-dependent gene expression in hippocampal neurons.
Footnotes
-
This work was supported by grants from the National Institute of Mental Health (to E.T.K.), and by Grant MH070727 from National Institute of Mental Health and by the National Alliance for Research on Schizophrenia and Depression (to L.M.M.).
-
M.A.M. and Y.S. contributed equally to this work.
-
doi:10.1124/jpet.105.097097.
-
ABBREVIATIONS: CRE, cAMP-responsive element; CREB, cAMP response element binding protein; PKA, protein kinase A; CaMK, calcium/calmodulin-dependent protein kinase; 5-HT, serotonin, 5-hydroxytryptamine; KT5720, (9S, 10S, 12R)-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9,12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic acid hexyl ester; PD98059, 2′-amino-3′methoxyflavone; KN92, 2-[N-(4′-methoxybenzenesulfonyl)]amino-N-(4′-chlorophenyl)-2-propenyl-N-methylbenzylamine phosphate; KN93, N-[2-[[[3-(4′-chlorophenyl)-2-propenyl]methylamino]methyl]phenyl]-N-(2-hydroxyethyl)-4′-methoxybenzenesulfonamide phosphate salt; FK-506, tacrolimus; WAY-100635, N-{2-[4-(2-methyoxyphenyl)-1-piperazinyl]ethyl}-N-2-pyridinylcyclo-hexanecarboxamide; SB269970, (R)-3-[2-[2-(4-methylpiperidin-1-yl)ethyl]pyrrolidine-1-sulfonyl]phenol hydrochloride; 5-CT, 5-carboxamidotryptamine maleate salt; 8-OH DPAT, 8-hydroxydipropylaminotetralin; QX-314, lidocaine N-ethylbromide; TTX, tetrodotoxin; PBS, phosphate-buffered saline; pCREB, phosphorylated CREB; DG, dentate gyrus; MEK, mitogen-activated protein kinase kinase; OA, okadaic acid; LTP, long-term potentiation; LTD, long-term depression; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; DA, dopamine.
-
↵1 Current affiliation: Department of Pharmacology, Hacettepe University Faculty of Medicine, Ankara, Turkey.
- Received October 13, 2005.
- Accepted December 23, 2005.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|